<DOC>
	<DOCNO>NCT02181335</DOCNO>
	<brief_summary>To establish least one two dos Budesonide , ethanolic solution inhale Respimat ® inhaler ( 100 200 mcg , 2 puff bid ) 12-week study period symptomatic moderate severe asthmatic patient , give therapeutic response , inferior obtain dose Budesonide inhale Turbohaler ® ( 200 mcg , 2 puff bid ) safety profile least good</brief_summary>
	<brief_title>Efficacy Safety Study Comparing Respimat ® Budesonide With Turbohaler ® Budesonide Symptomatic Adult Moderate Severe Asthmatics Requiring Inhaled Corticosteroids Bronchodilator Therapy</brief_title>
	<detailed_description />
	<mesh_term>Bronchodilator Agents</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Patients either sex age 18 65 year ( inclusive ) Nonsmokers ex smoker . HAVING stop smoke &gt; = 1 year prior screen smoke history &lt; = 10 pack year Diagnosis MODERATE SEVERE bronchial asthma duration least 6 month inclusion criterion 4 plus 5 diagnosis asthma accord WHO guideline least one year Increase asthma symptom ( wheeze , cough , shortness breath , chest tightness ) exposure follow stimulus : cold , dry air , dust , smoke , exercise allergen Patients stable dosage either 800 mcg &lt; = BDP ( beclomethasone dipropionate ) &lt; = 1600 mcg daily inhale steroid without inhale long act β2agonists oral xanthine screen visit 1 past 4 week short act β2agonists prn past 6 week 400 mcg &lt; = BDP &lt; 800 mcg daily inhale steroid inhale longacting β2agonists ( oral xanthine ) , screen visit 1 past 4 week short act β2agonists prn past 6 week FEV1 &gt; = 60 % &lt; = 90 % predict normal visit 1 withhold respiratory drug per section 4.2.1 . Predicted normal value base guideline standardize function test European Community Coal Steel ( ECCS ) Males : FEV1 pred . ( L ) = 4.30 x Height ( ) 0.029 x Age ( yr ) 2.49 Females : FEV1 pred . ( L ) = 3.95 x Height ( ) 0025 x Age ( yr ) 2.60 Patient must demonstrate improvement FEV 1 &gt; = 12 % baseline absolute change least 200 ml within 30 minute administration two puff salbutamol MDI ( meter dose inhaler ) ( 100 mcg per puff ) . Historical data within previous 6 month acceptable Patients must able trained proper use MDI , Turbohaler® Respimat® perform technically satisfactory pulmonary function test Patients must willing able give inform write consent prior participation trial i.e . prior prestudy washout usual pulmonary medication willing able complete entire study describe protocol Patients history seasonal exacerbation asthma suggest seasonal asthma would control medication allow protocol ( see 4.2.2 ) likely occur time period patient study History cardiovascular , renal , neurologic , liver , immunologic endocrine dysfunction clinically significant . A clinically significant disease define one opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study Patients recent history ( &lt; = 1 year ) myocardial infarction and/or ( &lt; = 3 year ) heart failure patient cardiac arrhythmia require drug therapy History cancer within past 5 year exclude treat basal cell carcinoma Patients current psychiatric disorder would interfere conduct trial Patients history presence glaucoma and/or posterior subcapsular cataract Patients undergone thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion criterion Patients active tuberculosis indication treatment Patients history cystic fibrosis , bronchiectasis , chronic bronchitis emphysema Patients active rhinitis require treatment intranasal steroid and/or ketotifen Patients upper respiratory tract infection past 6 week prior screen visit 1 result exacerbation asthma symptom Patients unstable asthma define follow : require hospitalization asthma exacerbation past 6 month , history lifethreatening asthma exacerbation result respiratory failure require intubation ICU admission longer 24 hour past 5 year Patients clinically signification abnormal baseline haematology , blood chemistry urinalysis ( abnormality define disease list exclusion criterion ) Patients abnormal laboratory value : SGOT ( serum glutamate oxaloacetate transaminase ) &gt; 200 % upper limit normal range SGPT ( serum glutamate pyruvate transaminase ) &gt; 200 % upper limit normal range Creatinine &gt; 125 % upper limit normal range Bilirubin &gt; 150 % upper limit normal range , exception Gilbert 's disease exclude regardless clinical condition Patients know intolerance hypersensitivity one aerosolize product include inhaled steroid ( budesonide beclomethasone dipropionate ) , salbutamol , ethylenediaminetetraacetic acid , ethanol , citric oleic acid Patients use oral systemic ( intramuscular intravenous ) corticosteroid past 8 week potent immunosuppressant ( i.e . methotrexate ) medication past 3 month Patients use beta blocker therapy , ACE inhibitor ( exception provide ACE inhibitor stable dose six month report incidence cough ) monoamine oxidase inhibitor , tricyclic antidepressant , cromolyn nedocromil sodium , ketotifen , astemizole antihistamine drug , combination inhale long act β2agonist plus oral xanthine receive influenza vaccine within 1 week Screening Visit 1 Patients nebulised β2agonists , anticholinergic steroids 4 week screen visit 1 If patient allergen desensitization therapy , maintenance dose previous 3 month continue throughout treatment period Unstable respiratory medication dosage last 4 week prior screen visit 1 Patients significant history and/or active alcohol drug abuse . Significant define opinion investigator may either put patient risk participation study may influence result study patient 's ability participate study Patients take investigational drug , one month six halflives ( whichever great ) prior Screening Visit Pregnant nursing woman sexually active woman childbearing potential use medically approve method contraception ( i.e . oral contraceptive , intrauterine device , diaphragm , Norplant® doublebarrier ) Previous participation randomise period study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>